Please ensure Javascript is enabled for purposes of website accessibility

Why Keryx Biopharmaceuticals Inc. Plunged 26% in January

By Brian Feroldi - Feb 9, 2016 at 5:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The one drug biopharma got caught up in January's biotech melt down.

What: Shares of Keryx Biopharmaceuticals (KERX), a renal disease-focused biopharmaceutical company, dropped more than 26% in the month of January, according to data from S&P Global Market Intelligence.

So what: There wasn't any news released during the month to justify the huge sell-off, so it appears that Keryx's stock simply got caught up in the general biotech beatdown.

A look at Keryx's stock during the month when compared to the SDPR S&P Biotech ETF (XBI -2.38%), itself an ETF that holds a few dozen biotechnology stocks, is telling.

KERX Chart

Now what: While the company didn't have any new information to share, its management team did give a presentation at the J.P. Morgan Healthcare Conference where it outlined its growth strategy for the year ahead. Management also confirmed that its previously announced sales force expansion has been completed. It now has 95 representatives targeting 5,000 prescribing physicians with increased frequency, which the company believes should help to drive more demand for Auryxia. In addition, it has successfully expanded the reimbursement landscape for Auryxia, which was a major barrier to early adoption.

Across the pond, Keryx has still not yet launched Fexeric -- Auryxia's European brand name -- as it is still actively looking for a partner in the region. 

Keryx has a number of catalysts coming in 2016 that could help its stock recover from a dreadful 2015. But, given that its near-term future is tied directly to the success of Auryxia, the company is likely to remain a very high-risk stock and should only be held by investors with a strong stomach for risk.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Keryx Biopharmaceuticals, Inc. Stock Quote
Keryx Biopharmaceuticals, Inc.
KERX
SPDR Series Trust - SPDR S&P Biotech ETF Stock Quote
SPDR Series Trust - SPDR S&P Biotech ETF
XBI
$92.64 (-2.38%) $-2.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.